A platform of three products that designs, qualifies, and orchestrates the lanes between every manufacturer and every patient — for biologics, cell & gene therapy, mRNA, radiopharmaceuticals and ATMPs.
The supply chain that carries it cannot stay a stack of spreadsheets, brokered emails, and Excel-bound qualification protocols. A CAR-T leukopak doesn't survive a 4-hour customs hold. A radiopharmaceutical doesn't wait for a Monday meeting. An mRNA dose doesn't tolerate a single broken cold-chain leg.
Every advanced therapy operates on tighter tolerances and tighter timelines than the last. Existing tools were built for cases, pallets, and weeks. LogXp is built for doses, lanes, and hours — for the precision and the audit trail that this generation of medicine demands.
NetXp is live in private beta. The rest are in development, drafted against the same data model and ready to plug into the same network you've already modeled.
Design the network, qualify the cold chain, and score the risk on every lane — for any modality. Author and sign Lane Risk Assessments. Trace every leukopak and every milliliter to the patient with the chain of identity intact.
Event-driven, vein-to-vein orchestration across every modality. One event stream from apheresis (or fill-finish) to infusion (or dispensing) — sensor telemetry, courier APIs, customs events, all stitched into a single timeline.
Network scenario modelling and supply-chain design of experiments. Stress-test every site, every lane, every demand curve before you commit a single capex dollar — and see where capacity runs hot before it costs you a patient.
One workspace for the networks your supply chain actually runs — not just the production lane.
Raw materials, APIs, intermediates and bulk drug. Batch-quantified, yield-variable, rarely serialized.
Marketed product to patients, pharmacies, and payer channels.
Investigator sites, CROs, and the IMP & patient-sample movement between them.
Bioanalytical, stability, and retention samples to test labs and biorepositories.
Working and primary standards to QC labs, CMOs, and method-development partners.
LogXp doesn't pick favorites. Every shape of medicine has its own supply chain — they all run on the same data model, the same audit log, the same AI.
Oral and injectable, ambient to 2–8°C. Volume in the millions, lead times in days.
mAbs, fusion proteins, recombinants. 2–8°C cold chain. Long-tail destinations and tight compliance.
Vaccines and therapeutics. −60 to −90°C ultra-cold. Bulk fan-out to dozens of markets.
PET and theranostics. Half-life governs everything. Hours from cyclotron to patient.
CAR-T, TIL, patient-specific cell therapy. Vein-to-vein. One patient, one product, one lane.
iPSC, off-the-shelf cell therapy. One donor batch, many recipients. Cryogenic at scale.
Gene reads. Genie acts. Both cite their sources, work only inside your tenant, and never sign a regulated document on your behalf.
For LRA-2847 (BOS→FRA, CTX-001): the lane has 47 prior shipments with zero excursions, and the modeled p99 worst case clears the 58h transport allowance with 10 hours of headroom. I've attached the sensor archive and the customs precedent for Q3.
Drafted a 4-step plan to re-qualify GRU→FRA with a second courier. Steps 1–2 ran in the sandbox; steps 3–4 are waiting on your approval before they touch your scenario branch or the courier portal.
A LogXp principle: AI surfaces and AI drafts — the human authors and signs. Every Gene answer cites its sources. Every Genie action is sandboxed, reversible, and pauses for human approval before it leaves the system. Every change lands in a 21 CFR Part 11 audit log. There is no autopilot for a regulated supply chain.
LogXp is for regulated supply chains. Every product ships with the audit, the validation, and the controls you'd already be building yourself.
E-signature, audit log, and access controls designed against FDA Part 11 from the first commit. Every Lane Risk Assessment is signed, locked, and traceable.
Security, availability, and confidentiality controls under continuous evidence collection. Type II audit in progress; SOC 2 Type I attestation available on request.
GAMP 5 categorized. Designed for validated environments — IQ/OQ/PQ traceability, change control, and access governance fit your QA's existing playbook.
ISO 27001 controls implemented across infrastructure, access, and data handling. Certification roadmap aligned with our Q3 2027 enterprise readiness milestone.
Talk to the LogXp team about what your supply chain could feel like when it knows you back.